Abstract:Background Recent literatures indicate that maternal hormone exposure is a risk factor for autism spectrum disorder (ASD). We hypothesize that prenatal progestin exposure may counteract the neuroprotective effect of estrogen and contribute to ASD development, and we aim to develop a method to ameliorate prenatal progestin exposure-induced autism-like behavior. Methods Experiment 1: Prenatal progestin exposure-induced offspring are treated with resveratrol (RSV) through either prenatal or postnatal exposure and then used for autism-like behavior testing and other biomedical analyses. Experiment 2: Prenatal norethindrone (NET) exposure-induced offspring are treated with ERβ knockdown lentivirus together with RSV for further testing. Experiment 3: Pregnant dams are treated with prenatal NET exposure together with RSV, and the offspring are used for further testing. Results Eight kinds of clinically relevant progestins were used for prenatal exposure in pregnant dams, and the offspring showed decreased ERβ expression in the amygdala with autism-like behavior. Oral administration of either postnatal or prenatal RSV treatment significantly reversed this effect with ERβ activation and ameliorated autism-like behavior. Further investigation showed that RSV activates ERβ and its target genes by demethylation of DNA and histone on the ERβ promoter, and then minimizes progestin-induced oxidative stress as well as the dysfunction of mitochondria and lipid metabolism in the brain, subsequently ameliorating autism-like behavior. Conclusions We conclude that resveratrol ameliorates prenatal progestin exposure-induced autism-like behavior through ERβ activation. Our data suggest that prenatal progestin exposure is a strong risk factor for autism-like behavior. Many potential clinical progestin applications, including oral contraceptive pills, preterm birth drugs, and progestin-contaminated drinking water or seafood, may be risk factors for ASD. In addition, RSV may be a good candidate for clinically rescuing or preventing ASD symptoms in humans, while high doses of resveratrol used in the animals may be a potential limitation for human application.

Resveratrol Alleviates Postpartum Depression-Like Behavior by Activating Autophagy Via SIRT1 and Inhibiting AKT/mTOR Pathway.

Inhibition of Autophagy in Microglia Alters Depressive-Like Behavior Via BDNF Pathway in Postpartum Depression

Resveratrol ameliorates estrogen deficiency-induced depression- and anxiety-like behaviors and hippocampal inflammation in mice

Progesterone and Fluoxetine treatments of postpartum depressive-like behavior in rat model.

Ameliorative effect of SIRT1 in postpartum depression mediated by upregulation of the glucocorticoid receptor

Activation of Sigma-1 Receptor Alleviates Postpartum Estrogen Withdrawal-Induced “Depression” Through Restoring Hippocampal nNOS-NO-CREB Activities in Mice

A postpartum model in rat: behavioral and gene expression changes induced by ovarian steroid deprivation

Activation of σ-1 receptor mitigates estrogen withdrawal-induced anxiety/depressive-like behavior in mice via restoration of GABA/glutamate signaling and neuroplasticity in the hippocampus

Resveratrol Abrogates Lipopolysaccharide-Induced Depressive-Like Behavior, Neuroinflammatory Response, and CREB/BDNF Signaling in Mice

Resveratrol Alleviates Depression-Like Behaviors by Inhibiting Ferroptosis Via AKT/NRF2 Pathway

Ameliorating Effect of Standardized Rice Bran Supplement on Depressive-Like Behaviors in Ovariectomized Mice

Resveratrol ameliorates prenatal progestin exposure-induced autism-like behavior through ERβ activation

Paeoniflorin exhibits antidepressant activity in rats with postpartum depression via the TSPO and BDNF‑mTOR pathways

Resveratrol Attenuates Chronic Unpredictable Mild Stress-Induced Alterations in the SIRT1/PGC1α/SIRT3 Pathway and Associated Mitochondrial Dysfunction in Mice

Effect of yuejuganmaidazaotang in hippocampus in postpartum depression model mice on AKT/mTOR signaling pathway

Postpartum depression animal model in mice and effect of Yuejuganmaidazaotang on PPD model

Resveratrol Reverses Chronic Restraint Stress-Induced Depression-Like Behaviour: Involvement of BDNF Level, ERK Phosphorylation and Expression of Bcl-2 and Bax in Rats.

Antidepressant-like activity of resveratrol treatment in the forced swim test and tail suspension test in mice: The HPA axis, BDNF expression and phosphorylation of ERK

Resveratrol ameliorates maternal immune activation-associated cognitive impairment in adult male offspring by relieving inflammation and improving synaptic dysfunction

Mangiferin Alleviates Postpartum Depression–Like Behaviors by Inhibiting MAPK Signaling in Microglia

Resveratrol Exerts Antidepressant Properties in the Chronic Unpredictable Mild Stress Model Through the Regulation of Oxidative Stress and Mtor Pathway in the Rat Hippocampus and Prefrontal Cortex.